JP2023522166A - メニン阻害剤とｃｙｐ３ａ４阻害剤との組合せ、およびその使用方法 - Google Patents

メニン阻害剤とｃｙｐ３ａ４阻害剤との組合せ、およびその使用方法 Download PDF

Info

Publication number
JP2023522166A
JP2023522166A JP2022561040A JP2022561040A JP2023522166A JP 2023522166 A JP2023522166 A JP 2023522166A JP 2022561040 A JP2022561040 A JP 2022561040A JP 2022561040 A JP2022561040 A JP 2022561040A JP 2023522166 A JP2023522166 A JP 2023522166A
Authority
JP
Japan
Prior art keywords
inhibitor
menin
cyp3a4
administered
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522166A5 (enExample
Inventor
マクギーハン，ジェラード・エム
オルデントリヒ，ピーター
ローゼン，ガリト
スミス，スティーブン・エイ
Original Assignee
シンダックス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンダックス ファーマシューティカルズ， インコーポレイテッド filed Critical シンダックス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023522166A publication Critical patent/JP2023522166A/ja
Publication of JP2023522166A5 publication Critical patent/JP2023522166A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022561040A 2020-04-07 2021-04-07 メニン阻害剤とｃｙｐ３ａ４阻害剤との組合せ、およびその使用方法 Pending JP2023522166A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006574P 2020-04-07 2020-04-07
US63/006,574 2020-04-07
PCT/US2021/026141 WO2021207335A1 (en) 2020-04-07 2021-04-07 Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023522166A true JP2023522166A (ja) 2023-05-29
JP2023522166A5 JP2023522166A5 (enExample) 2024-04-16

Family

ID=78023861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561040A Pending JP2023522166A (ja) 2020-04-07 2021-04-07 メニン阻害剤とｃｙｐ３ａ４阻害剤との組合せ、およびその使用方法

Country Status (10)

Country Link
US (1) US12564590B2 (enExample)
EP (1) EP4132932A4 (enExample)
JP (1) JP2023522166A (enExample)
KR (1) KR20230007359A (enExample)
CN (3) CN120393025A (enExample)
AU (1) AU2021252552A1 (enExample)
CA (1) CA3178691A1 (enExample)
IL (1) IL297039A (enExample)
MX (1) MX2022012471A (enExample)
WO (1) WO2021207335A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214367A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
EP4132932A4 (en) 2020-04-07 2024-04-17 Syndax Pharmaceuticals, Inc. COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
IL308476A (en) 2021-05-14 2024-01-01 Syndax Pharmaceuticals Inc Inhibitors of the menin-mil interaction
US20250152591A1 (en) * 2022-02-04 2025-05-15 Kura Oncology, Inc. Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors
US20250295661A1 (en) * 2022-05-09 2025-09-25 Syndax Pharmaceuticals, Inc. Menin-mll inhibitors for the treatment of cancer
CN120456907A (zh) * 2022-11-02 2025-08-08 库拉肿瘤学公司 急性白血病的治疗方法
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
WO2025106862A1 (en) * 2023-11-17 2025-05-22 Kura Oncology, Inc. Methods of treating kit positive cancers with a menin inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175746A1 (en) * 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
JP2019517548A (ja) * 2016-06-10 2019-06-24 ヴァイティー ファーマシューティカルズ，エルエルシー メニン−ｍｌｌ相互作用の阻害剤

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5820915A (en) 1996-06-27 1998-10-13 Bioavailability Systems, L.L.C. Method for the preparation of a first-pass effective citrus-derived substance and product thereof
US6124477A (en) 1996-06-27 2000-09-26 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5990154A (en) 1997-05-30 1999-11-23 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds and citrus extract
US6248776B1 (en) 1997-08-26 2001-06-19 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US6063809A (en) 1997-08-26 2000-05-16 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5993887A (en) 1998-06-29 1999-11-30 Bioavailability Systems, L.L.C. Safe citrus juice and process for preparation
WO2004037827A1 (en) 2000-10-20 2004-05-06 Bioavailability Systems, Llc Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2007528423A (ja) 2004-03-11 2007-10-11 セコイア、ファーマシューティカルズ、インコーポレイテッド 耐性防止レトロウイルスプロテアーゼ阻害薬
US7378441B2 (en) 2004-05-07 2008-05-27 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
MX354412B (es) 2011-06-10 2018-03-05 Merck Patent Gmbh Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
US9458124B2 (en) 2013-02-06 2016-10-04 Wayne State University Substituted pyran derivatives
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US11596636B2 (en) 2014-01-14 2023-03-07 The Trustees Of The University Of Pennsylvania Tailored combinatorial epigenetic therapies for P53 gain-of-function tumors
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
AU2015301746A1 (en) * 2014-08-13 2017-02-16 Celgene Corporation Combination therapy for treating cancer
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
US10869868B2 (en) 2016-01-26 2020-12-22 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
ES2990061T3 (es) * 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
AU2017326006B2 (en) 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
EP3774731A4 (en) 2018-03-30 2021-11-24 The Regents Of The University Of Michigan PIPERIDINE COMPOUNDS AS COVALENT MENINE INHIBITORS
AU2019337547A1 (en) 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
EP4132932A4 (en) 2020-04-07 2024-04-17 Syndax Pharmaceuticals, Inc. COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
US20240238291A1 (en) 2021-05-12 2024-07-18 Syndax Pharmaceuticals, Inc. Combinations for treatment of cancer
IL308476A (en) 2021-05-14 2024-01-01 Syndax Pharmaceuticals Inc Inhibitors of the menin-mil interaction
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑
CN118234497A (zh) 2021-12-15 2024-06-21 丹娜-法伯癌症研究所 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist)
WO2025049521A2 (en) 2023-08-28 2025-03-06 Syndax Pharmaceuticals, Inc. Aryl ether analogs as inhibitors of the menin-mll interaction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517548A (ja) * 2016-06-10 2019-06-24 ヴァイティー ファーマシューティカルズ，エルエルシー メニン−ｍｌｌ相互作用の阻害剤
WO2018175746A1 (en) * 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRUG METAB DISPOS, vol. 46, JPN6025013649, 2018, pages 1329 - 1337, ISSN: 0005772312 *
岡山医学会雑誌, vol. 119, JPN6025013647, 2008, pages 319 - 322, ISSN: 0005772311 *

Also Published As

Publication number Publication date
US12564590B2 (en) 2026-03-03
CN115698013B (zh) 2026-01-02
MX2022012471A (es) 2022-11-30
EP4132932A1 (en) 2023-02-15
CN120393025A (zh) 2025-08-01
KR20230007359A (ko) 2023-01-12
IL297039A (en) 2022-12-01
CA3178691A1 (en) 2021-10-14
US20230165858A1 (en) 2023-06-01
EP4132932A4 (en) 2024-04-17
WO2021207335A1 (en) 2021-10-14
CN120393026A (zh) 2025-08-01
AU2021252552A1 (en) 2022-10-27
CN115698013A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
JP7795513B2 (ja) ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
US12564590B2 (en) Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof
US20240238291A1 (en) Combinations for treatment of cancer
JP6506555B2 (ja) ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
US20160022683A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
KR20200017549A (ko) 브루톤 타이로신 키나아제 저해제의 결정 형태
EP3236968A1 (en) Btk inhibitor combinations and dosing regimen
CN108024996A (zh) 布鲁顿氏酪氨酸激酶抑制剂组合和其用途
CN108135904A (zh) 用于治疗多发性骨髓瘤的btk抑制剂组合
CN117642168A (zh) 布鲁顿酪氨酸激酶的抑制剂及其使用方法
HK40102175A (zh) 布鲁顿酪氨酸激酶的抑制剂及其使用方法
HK1185279A (en) The use of inhibitors of bruton's tyrosine kinase (btk)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260115